文献速递淋巴瘤

赞达利布联合赞布替尼治疗经治滤泡性淋巴瘤和套细胞淋巴瘤的安全性与疗效

Safety and efficacy of zandelisib plus zanubrutinib in previously treated follicular and mantle cell lymphomas.
PubMed 文献 · Br J Haematol · 2024-03-19

这项1期研究评估了PI3Kδ抑制剂赞达利布联合BTK抑制剂赞布替尼在复发/难治B细胞恶性肿瘤中的安全性及疗效,推荐2期剂量为赞达利布60 mg第1-7天联合赞布替尼80 mg每日两次持续给药,28天为一周期。滤泡性淋巴瘤总缓解率87%(完全缓解33%),套细胞淋巴瘤总缓解率74%(完全缓解47%);中位缓解持续时间和无进展生存期两组均未达到;估计1年无进展生存率滤泡性淋巴瘤为72.3%(95%CI 51.9-85.1),套细胞淋巴瘤为56.3%(95%CI 28.9-76.7)。

要点

  • 推荐2期剂量为赞达利布60 mg第1-7天联合赞布替尼80 mg每日两次持续给药,28天为一周期。
  • 滤泡性淋巴瘤总缓解率87%(完全缓解33%),套细胞淋巴瘤总缓解率74%(完全缓解47%)。
  • 两组中位缓解持续时间和无进展生存期均未达到;3例患者因不良事件停药。

核心结论

  • 赞达利布联合赞布替尼与高缓解率相关,且与任一单药相比毒性未增加。

研究设计与样本

  • 1期研究(NCT02914938),包括剂量探索阶段(复发/难治B细胞恶性肿瘤,n=20)和疾病特异性扩展队列(滤泡性淋巴瘤n=31,套细胞淋巴瘤n=19)。

主要发现

  • 总人群中常见不良事件(所有级别/3-4级)包括中性粒细胞减少(35%/24%)、腹泻(33%/2%)、血小板减少(32%/8%)、贫血(27%/8%)、肌酐升高(25%/0%)、挫伤(21%/0%)、疲乏(21%/2%)、恶心(21%/2%)和天冬氨酸氨基转移酶升高(24%/6%)。
  • 3例患者因不良事件停药。
  • 滤泡性淋巴瘤总缓解率87%(完全缓解33%),套细胞淋巴瘤总缓解率74%(完全缓解47%)。
  • 两组中位缓解持续时间和无进展生存期均未达到。
  • 估计1年无进展生存率滤泡性淋巴瘤为72.3%(95%CI 51.9-85.1),套细胞淋巴瘤为56.3%(95%CI 28.9-76.7);中位随访时间分别为16.5个月和10.9个月。

关键数值与推荐

  • 推荐2期剂量为赞达利布60 mg第1-7天联合赞布替尼80 mg每日两次持续给药,28天为一周期。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The combination of the phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor zandelisib with the Bruton's tyrosine kinase (BTK) inhibitor zanubrutinib was hypothesized to be synergistic and prevent resistance to single-agent therapy. This phase 1 study (NCT02914938) included a dose-finding stage in patients with relapsed/refractory (R/R) B-cell malignancies (n = 20) and disease-specific expansion cohorts in follicular lymphoma (FL; n = 31) or mantle cell lymphoma (MCL; n = 19). The recommended phase 2 dose was zandelisib 60 mg on Days 1-7 plus zanubrutinib 80 mg twice daily continuously in 28-day cycle. In the total population, the most common adverse events (AEs; all grades/grade 3-4) were neutropenia (35%/24%), diarrhoea (33%/2%), thrombocytopenia (32%/8%), anaemia (27%/8%), increased creatinine (25%/0%), contusion (21%/0%), fatigue (21%/2%), nausea (21%/2%) and increased aspartate aminotransferase (24%/6%). Three patients discontinued due to AEs. The overall response rate was 87% (complete response [CR] = 33%) for FL and 74% (CR = 47%) for MCL. The median duration of response and progression-free survival (PFS) were not reached in either group. The estimated 1-year PFS was 72.3% (95% confidence interval [CI], 51.9-85.1) for FL and 56.3% (95% CI, 28.9-76.7) for MCL (median follow-up: 16.5 and 10.9 months respectively). Zandelisib plus zanubrutinib was associated with high response rates and no increased toxicity compared to either agent alone.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Soumerai JD, Diefenbach CS, Jagadeesh D, et al. Safety and efficacy of zandelisib plus zanubrutinib in previously treated follicular and mantle cell lymphomas. Br J Haematol. 2024. PMID: 38500476. doi:10.1111/bjh.19419

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。